Threshold Pharmaceuticals

(

THLD

) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 1.3%. By the end of trading, Threshold Pharmaceuticals rose 26 cents (3.8%) to $7.20 on average volume. Throughout the day, 2.8 million shares of Threshold Pharmaceuticals exchanged hands as compared to its average daily volume of 2.5 million shares. The stock ranged in a price between $6.68-$7.32 after having opened the day at $6.88 as compared to the previous trading day's close of $6.94. Other companies within the Drugs industry that increased today were:

AspenBio Pharma

(

APPY

), up 21.9%,

Zogenix

(

ZGNX

), up 15.7%,

Ampio Pharmaceuticals

(

AMPE

), up 11.7%, and

Opexa Therapeutics

(

OPXA

), up 8.9%.

Threshold Pharmaceuticals, Inc., a development stage company, focuses on the discovery and development of drugs for the microenvironment of solid tumors and the bone marrows of hematologic malignancies as novel treatments for patients living with cancer. Threshold Pharmaceuticals has a market cap of $370.6 million and is part of the

health care

sector. Shares are up 468.9% year to date as of the close of trading on Tuesday. Currently there are three analysts that rate Threshold Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Threshold Pharmaceuticals as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and deteriorating net income.

On the negative front,

iBio

(

IBIO

), down 13.2%,

Rosetta Genomics

(

ROSG

), down 11.8%,

Complete Genomics

(

GNOM

), down 11.5%, and

Medgenics

(

MDGN

), down 10.3%, were all losers within the drugs industry with

Pfizer

(

PFE

) being today's drugs industry loser.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

null